| Molecular formula | C194H304N48O61 |
|---|
| Molecular weight | 4285 g/mol |
|---|
| Registered trials | 14 |
|---|
| PubChem CID | 162625103 |
|---|
Regulatory status
Ecnoglutide, also known by the development codes XW003 and VRB-101, is an investigational compound. It does not have an approved drug label, and no regulatory agency has cleared it for medical use.
What ecnoglutide is
Ecnoglutide is a large synthetic peptide with the molecular formula C194H304N48O61 and a molecular weight of approximately 4,285 g/mol. Its structure includes a chain of linked amino acid residues along with a fatty acid side chain, a feature often used to extend a peptide's activity. The compound is catalogued under PubChem CID 162625103. Because no approved label exists, there is no established mechanism, indication, or dosing information to report.
Trial footprint
Fourteen registered clinical trials reference ecnoglutide. Among the studies on record, a Phase 3 trial (NCT05680155) evaluating ecnoglutide against placebo in patients with type 2 diabetes mellitus has been completed. A Phase 3 trial (NCT07387094) is currently recruiting to study ecnoglutide in obese participants with obstructive sleep apnea who are not on positive airway pressure therapy. A separate Phase 2 trial (NCT07553299) examining a weekly oral dose for weight maintenance in participants with obesity or overweight and weight-related comorbidities is active but no longer recruiting.
FAQ
No. Ecnoglutide is an investigational compound and does not currently have an approved drug label from any regulatory agency. It is being studied in clinical trials, but its safety and effectiveness for any use have not been established through an approval process.
Ecnoglutide has been studied under the development codes XW003 and VRB-101. These names may appear interchangeably in clinical trial listings and research materials.
Registered trials have examined ecnoglutide in people with type 2 diabetes mellitus and in people with obesity or overweight, including those with obstructive sleep apnea. These are research uses only and do not reflect an approved indication.
As of the most recent data pull, fourteen clinical trials reference ecnoglutide, spanning different phases and study designs.
Ecnoglutide is a large synthetic peptide with a molecular weight of approximately 4,285 g/mol. Its structure includes a fatty acid side chain attached to a peptide backbone, a design feature seen in several long-acting peptide compounds.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 162625103 ClinicalTrials.gov (NCT05680155, NCT07553299, NCT07387094) ChEMBL
Updated 2026-09-19